Please ensure Javascript is enabled for purposes of website accessibility

Why Fate Therapeutics Tumbled 23.9% in March

By Maxx Chatsko - Apr 9, 2020 at 8:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The development-stage pharma company gave up a good chunk of its gains from recent months, but roared back in April.

What happened

Shares of Fate Therapeutics (FATE 0.71%) dropped nearly 24% last month, according to data provided by S&P Global Market Intelligence. That was almost twice the fall of the S&P 500, which declined 12.5% in March due to the abrupt uncertainty ushered in by the coronavirus pandemic. 

Investors can't be too surprised by the stock's fall. Fate Therapeutics is a development-stage company with no product revenue. What's more, shares had gained nearly 80% from September 2019 through February of this year on promising clinical data, albeit from early stage studies. 

In other words, the pharma stock had plenty of fragile gains to give back, although it clawed its way back in early April on the heels of a lucrative partnership.

A businessman holding out his hand and a declining bar chart hovering over it.

Image source: Getty Images.

So what

In early April, Fate Therapeutics announced a collaboration with Johnson & Johnson subsidiary Janssen Pharmaceutica. The deal included a $50 million equity investment and a $50 million up-front cash payment. Fate Therapeutics is also eligible to receive up to $1.8 billion in development and regulatory milestone payments, up to $1.2 billion in commercial milestone payments, and double-digit royalties on future sales. 

Bringing a deep-pocketed partner on board helps to significantly de-risk operations. Fate Therapeutics might now have a substantial revenue stream to use as it develops wholly owned assets. Considering the company lists 13 unique pipeline programs on its website, there are plenty of wholly owned assets in need of funding.

Now what

Fate Therapeutics maintains an above-average risk profile. After all, none of the programs being pursued with Janssen are guaranteed to work, although the development-stage company should be able to wrangle a decent amount of payments out of the collaboration just for advancing assets into clinical trials. Investors should also prepare for the company's ongoing clinical trials to be delayed or disrupted by the coronavirus pandemic, but the long-term potential of the pipeline remains intact.

Maxx Chatsko owns shares of Fate Therapeutics. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fate Therapeutics, Inc. Stock Quote
Fate Therapeutics, Inc.
$32.65 (0.71%) $0.23
Johnson & Johnson Stock Quote
Johnson & Johnson
$167.14 (-2.07%) $-3.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.